Prostate cancer and hormonal treatment
Clinical research includes metastatic hormone-sensitive prostate cancer, castration-resistant prostate cancer, high-risk localized prostate cancer, and metastatic disease to bone, with interest in androgen deprivation therapy, anti-androgen agents, GnRH antagonists, and treatment strategies linked to PSA response and disease control.
- Hormone therapy
- Androgen receptor pathway inhibition
- Bone-metastatic disease
Research also extends to symptom management during endocrine treatment and combinations with radiotherapy or radiopharmaceuticals.
Breast cancer and endocrine-sensitive disease
The sponsor funds studies in early breast cancer, ER-positive HER2-negative breast cancer, and localized or locally advanced disease, with emphasis on endocrine therapy, relapse prevention, and supportive care for treatment-related symptoms.
- Endocrine-sensitive breast cancer
- Adjuvant systemic treatment
- Quality of life
Additional interest includes approaches that integrate CDK4/6 inhibition and strategies aimed at delaying metastatic spread.
Head and neck cancer, lung cancer, and thoracic malignancies
Research activity covers squamous cell carcinoma of the head and neck, oropharyngeal squamous cell carcinoma, non-small cell lung cancer, oligometastatic NSCLC, thymic carcinoma, and type B3 thymoma, with interest in immunotherapy, radiotherapy, and combined modality treatment.
- Immune checkpoint therapy
- Locoregional control
- Thoracic oncology
Studies also address HPV-positive disease and limited metastatic burden in solid tumors.
Melanoma, skin lymphoma, and rare skin-related cancers
The portfolio includes BRAF V600 mutation–positive melanoma, uveal melanoma, and cutaneous T-cell lymphoma, with work focused on immunotherapy, targeted therapy, and skin-directed treatment approaches.
- Melanoma immunotherapy
- Targeted treatment combinations
- Cutaneous lymphoproliferative disease
Interest also extends to adjuvant treatment and disease control after local therapy in ocular and skin malignancies.
Central nervous system, sarcoma, and other rare cancers
Trials address glioblastoma, medulloblastoma, IDH-mutant astrocytoma, recurrent meningioma, renal cell carcinoma, germ cell tumors, and retroperitoneal sarcoma, with interest in radiation-based treatment, chemotherapy, radiopharmaceuticals, and disease-specific systemic therapy.
- Neuro-oncology
- Sarcoma management
- Rare tumor treatment
Research also includes renal cancer and germ cell malignancies requiring salvage or post-surgical treatment strategies.
